News

Zacks Investment Research on MSN20h
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...
Fierce Pharma21h
After Novo and Lilly resolved GLP-1 shortages, where does the compounding industry stand? Experts weigh in
Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...